After reviewing MAPS’ letter, Dr. James Baldwin of the WIRB informed Rick Doblin that the October 30 meeting was canceled, but not for the reasons MAPS had hoped. Dr. James Baldwin said that the meeting was “premature” because the WIRB now needed to convene its Executive Policy Committee (EPC) to discuss whether the WIRB should be involved with research with Schedule I drugs. The next EPC meeting is scheduled for November 19. The WIRB is no longer reviewing the protocol based on the science but on non-scientific, internal policy issues, not a very encouraging development.
